Clindamycin hydrochloride (oral): Difference between revisions
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
'''| [[Clindamycin hydrochloride adverse reactions|Adverse Reactions]]''' | '''| [[Clindamycin hydrochloride adverse reactions|Adverse Reactions]]''' | ||
'''| [[Clindamycin hydrochloride overdosage|Overdosage]]''' | '''| [[Clindamycin hydrochloride overdosage|Overdosage]]''' | ||
'''| [[Clindamycin hydrochloride dosage and administration|Dosage and Administration]]''' | '''| [[Clindamycin hydrochloride dosage and administration|Dosage and Administration]]''' | ||
'''| [[Clindamycin hydrochloride how supplied|How Supplied]]''' | '''| [[Clindamycin hydrochloride how supplied|How Supplied]]''' | ||
'''| [[Clindamycin hydrochloride labels and packages|Labels and Packages]]''' | '''| [[Clindamycin hydrochloride labels and packages|Labels and Packages]]''' | ||
Revision as of 17:11, 9 January 2014
| Clindamycin hydrochloride |
|---|
| CLEOCIN HYDROCHLORIDE® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Clindamycin (rINN) (IPA: [klɪndəˈmaɪsən]) is a lincosamide antibiotic used in the treatment of infections caused by susceptible microorganisms. Clindamycin is a semisynthetic antibiotic derived from lincomycin by 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the lincomycin. Clindamycin is marketed under various trade names including Dalacin (Pfizer), Cleocin (Pfizer), and in a foam as Evoclin (Connetics) and Duac(Stiefel).
Category
US Brand Names
CLEOCIN HYDROCHLORIDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50162s082,50441s045,50639s013lbl.pdf